FXR2 and neoplasm: Although no other significant correlations were found with the remaining clinicopathological parameters, FXR2 can be seen to be overexpressed in tumor sizes ≥ 10 mm (64.3%), in TNM stage IIB (90.9%), and in negative lymph nodal status (64%) (Table 1).